Institut Claudius Regaud

Running trials

• Not yet recruiting

  Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

  NCT07097064· Phase 2· Source

• Recruiting

  Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer

  NCT07821879· Source

• Recruiting

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· Phase 2· Source

• Recruiting

  TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)

  NCT06924099· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

  NCT05552001· Phase 3· Source

• Active, not recruiting

  A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

  NCT05879978· Phase 1· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Active, not recruiting

  A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

  NCT05625399· Phase 3· Source

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Source

• Recruiting

  Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

  NCT05867004· Source

• Recruiting

  ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

  NCT04916613· Phase 3· Source

• Active, not recruiting

  HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

  NCT05180695· Phase 1/2· Source

• Active, not recruiting

  177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

  NCT05204927· Phase 3· Source

• Recruiting

  Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

  NCT05183984· Phase 2· Source

• Recruiting

  Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  NCT04747054· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

  NCT04931342· Phase 2· Source

• Active, not recruiting

  Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

  NCT04603001· Phase 1· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· Source

• Active, not recruiting

  Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

  NCT03870919· Source

• Recruiting

  Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

  NCT03830788· Source

• Active, not recruiting

  ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

  NCT03570021· Phase 3· Source

• Active, not recruiting

  Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

  NCT03474094· Phase 2· Source

• Active, not recruiting

  Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

  NCT03333356· Source

• Active, not recruiting

  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  NCT03774732· Phase 3· Source

• Active, not recruiting

  Stereotactic Body Radiotherapy for the Treatment of OPD

  NCT03256981· Phase 2/3· Source

• Recruiting

  Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

  NCT03848052· Source

• Active, not recruiting

  National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

  NCT02867033· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Source

• Recruiting

  Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

  NCT03275311· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· Source

• Recruiting

  French Childhood Cancer Survivor Study

  NCT01620372· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Ovarian cancer4 recruiting
• Prostate cancer4 recruiting
• Head and neck cancer3 recruiting
• Lung cancer3 recruiting
• Melanoma3 recruiting
• Cervical cancer2 recruiting
• Endometrial cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Pancreatic cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

  NCT06211257· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· Source

• Completed

  Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck

  2023-503270-20-00· Phase 1· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Source

• Completed

  Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

  NCT05800964· Phase 1· Source

• Completed

  Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT05673057· Phase 1· Source

• Recruiting

  Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2022-501876-24-00· Phase 1· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Source

• Completed

  Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents

  NCT05151718· Source

• Completed

  Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer

  2022-500418-24-00· Phase 2/3· Source

• Completed

  Study of DF1001 in Patients With Advanced Solid Tumors

  NCT04143711· Phase 1/2· Source

• Completed

  Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

  NCT04132960· Phase 2· Source

• Completed

  Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC

  NCT03834493· Phase 3· Source

• Terminated

  Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

  NCT04234113· Phase 1· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  NCT03869190· Phase 1/2· Source

• Completed

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· Phase 2· Source

• Completed

  Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

  NCT03818061· Phase 2· Source

• Completed

  UTOLA: UTerin OLAparib

  NCT03745950· Phase 2· Source

• Completed

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· Source

• Completed

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· Phase 3· Source

• Completed

  PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

  NCT03275506· Phase 2· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Source

• Completed

  Cost Utility of Radical Surgery in Ovarian Cancer

  NCT02854215· Source

• Completed

  Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

  NCT02704832· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

• Completed

  Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

  NCT02266420· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source

• Completed

  Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· Phase 3· Source